Concepedia

Jan Cosaert

JC

22

Publications

2K

Citations

18

H-Index

1994

Active since

Affiliations

Eli Lilly (United States)(Current)

The University of Texas MD Anderson Cancer Center

AstraZeneca (United States)

AstraZeneca (United Kingdom)

Washington University in St. Louis

Jan Cosaert is an author at Eli Lilly (United States) specializing in medicine, oncology, and radiation oncology.

Top concepts

Publications per year

1994–2025

22

Publications

22

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

Eric Van Cutsem, Walter L. Vervenne, Jaafar Bennouna et al. · Journal of Clinical Oncology · 2009 · 642 citations · Full text

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

William D. Tap, Robin L. Jones, Brian A. Van Tine et al. · The Lancet · 2016 · 582 citations

, , +7

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

Thomas Powles, Danielle Carroll, Simon Chowdhury et al. · Nature Medicine · 2021 · 108 citations

, , +10

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park et al. · Nature Medicine · 2024 · 102 citations · Full text

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Anthony W. Tolcher, Jordan Berlin, Jan Cosaert et al. · Cancer Chemotherapy and Pharmacology · 2017 · 99 citations · Full text

, , +8

Rows per page

1–5 of 22